New targets for anti-inflammatory drugs

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 489-494

  Lewis, Alan J ^a   Manning, Anthony M ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; TRANSCRIPTION FACTOR;

AUTOIMMUNE DISEASE; CELL PROLIFERATION; DRUG ABSORPTION; DRUG ACTIVATION; DRUG DEVELOPMENT; DRUG TARGETING; ENTERITIS; HUMAN; INFLAMMATION; MEDIATOR RELEASE; MULTIPLE SCLEROSIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TISSUE DEGENERATION;

EID: 0033178332     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80071-4     Document Type: Article

References (56)

1. Drazen JM, Israel E, O'Byrne PM: Drug therapy: Treatment of asthma with drugs modifying the leukotriene pathway. New Engl J Med 1999, 340:197-206.
2. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
3. Feldmann M, Charles P, Taylor P, Maini RN: Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol 1998, 20:211-228.
4. O'Dell JR: Anticytokine therapy - A new era in the treatment of rheumatoid arthritis. New Engl J Med 1999, 340:310-312.
5. Van Hogezand RA, Verspaget HW: The future role of anti-tumor necrosis factor-alpha products in the treatment of Crohn's disease. Drugs 1998, 56:299-305.
6. Feldmann M, Elliott MH, Woody JN, Maini RN: Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997, 64:283-350.
7. c fusion protein. New Engl J Med 1997, 337:141-147.
8. Badger AM, Adams JL: New treatments for arthritis. Annu Rept Med Chem 1998, 33:203-212.
9. Black R, Bird TA, Mahler JM: Agents that block TNF-α synthesis or activity. Annu Rept Med Chem 1997, 32:241-250.
10. Carballo E, Lai WS, Blackshear PJ: Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin. Science 1998, 281:1001-1005.
11. Van de Loo AAJ, van den Berg WB: Effects of murine recombinant interleukin 1 but not tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatiol 1995, 22:2250-2258.
12. Bresnihan B, Alvaro-Garcia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arth Rheum 1998, 41:2196-2204. Clinical evaluation of IL-1Ra (Antril), an IL-1 receptor antagonist, demonstrates efficacy and safety in a large cohort of patients with active and severe RA. IL-1 Ra is the first biological agent to demonstrate a beneficial effect on the rate of joint erosion.
13. Joosten LAB, Helsen MMA, Van de Loo FAJ, Van de Berg WB: Anticytokine treatment of established type II collagen induced arthritis in DBAP/1 mice: A comparative study using anti-TNF-α, IL-1α1B, and IL-1Ra. Arth Rheum 1996, 39:797-809.
14. Evans CH, Ghivizzani SC, Robbins PD: Review: Gene therapy for rheumatic diseases. Arth Rheum 1999, 42:1-16.
15. Baggiolini M, Dewald B, Moser B: Human chemokines: An update. Annu Rev Immunol 1997, 15:675-705.
16. Baggiolini M: Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
17. Saunders J, Tarby CM: Opportunities for novel therapeutic agents acting at chemokine receptors. Drug Discov Today 1999, 4:80-92. This paper reviews this extensive receptor family and the approaches used to modulate these targets.
18. Manning AM, Rao A: Agents targeting transcription factors. In Inflammation: Basic Principles and Clinical Correlates. Edited by Gallin JI, Snyderman R. Philadelphia: Lippincott, Williams and Wilkins; 1999:in press.
19. Firestein GS, Manning AM: Signal transduction and transcription factors in rheumatic disease. Arth Rheum 1999, 42:609-621.
20. Whitmarsh AJ, Davis RJ: Transcription factor AP-1 regulation by mitogen-activated protein kinese signal transduction pathways. J Mol Med 1996, 74:589-607.
21. Treisman R: Regulation of transcription by MAP kinase cascades. Curr Opin Genet Dev 1996, 4:96-101.
22. Schaeffer HJ, Weber MJ: Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol Cell Biol 1999, 4:2435-2444.
23. Ip YT, Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development. Curr Opin Cell Biol 1998, 10:205-219. This reviews the important role played by the JNK signaling pathway in cell proliferation, apoptosis and tissue morphogenesis.
24. Whitmarsh AJ, Davis RJ: Structural organization of MAP kinase signaling modules by scaffold proteins in yeast and mammals. Trends Biochem Sci 1 998, 23:481-485. Scaffold proteins have been recently identified in mammalian cells that facilitate MAPK activation and insulate MAPK modules to ensure signaling specifity.
25. Karin M, Zheng-Gang L, Ebrahim Z: AP-1 function and regulation. Curr Opin Cell Biol 1997, 9:240-248.
26. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, Rakic P, Flavell RA: Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the JNK3 gene. Science 1997, 389:865-870.
27. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA: Defective T cell differentiation in the absence of JNK1. Science 1998, 282:2092-2095. This is the first description of JNK1-deficient mice and demonstrates that JNK1 signaling plays a critical role in T cell receptor-initiated T helper cell proliferation, apoptosis and differentiation.
28. + T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998, 9:575-585. JNK2-deficient mice revealed an important role of JNK2 in Th1 and Th2 responses. JNK2 is required for productive interferon γ in Th1 cells but not for IL-4 production in Th2 cells.
29. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
30. Young PR: Pharmacological modulation of cytokine action and production through signaling pathways. Cyt Growth Factor Rev 1998, 9:239-257.
31. Cuenda A, Cohen P, Buee-Scherrer V, Goedert M: Activation of stress activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J 1997, 16:295-305.
32. Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, Di Padova F, Ulevitch RJ, Han J: Characterization of the structure and function of the fourth member of p38 group mitogen - Activated protein kinase, p38δ. J Biol Chem 1997, 272:30122-30128.
33. Cohen P: The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol 1997, 7:353-361.
34. 50 ∼60 nM).
35. 50 ∼60 nM) and is a very effective blocker of T cell activation and/or proliferation.
36. Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR: Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 1998, 273:15605-15610.
37. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Gallulo V, Bemis GW, Fitzgibbon MJ, Caron PR, Murko MA: The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997, 4:423-431.
38. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M: Conversion of SB 203580 insensitive MAP kinase family members to drug-sensitive forms by a single amino acid substitution. Chem Biol 1998, 5:321-328. These finding explain how p38 inhibitors of the pyridinylimidazole class ATP-binding site in p38α and β but not in other MAPK family members.
39. Hacker C, Sidler K, Luell S, Widmer WR, MacCoss M, O'Keefe SJ, Mantlo N, O'Neill EA, Orevillo C, de Laszlo SE et al.: Pyrroles and other heterocycles as inhibitors of p38 kinase. J Bioorg Med Chem Lett 1998, 8:2689-2694.
40. Henry JR, Rubert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, et al.: 6-amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ68356]: A potent and selective p38 kinase inhibitor. J Med Chem 1998, 41:4196-4198.
41. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol Endocrinol 1997, 11:1245-1255.
42. Zhou X-F, Shen X-Q, Shemshedini L: Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/ C-Fos dimerization. Mol Endocrinol 1999, 13:276-285.
43. Caelles C, Gonzalez-Sancho JM, Munoz A: Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 1997, 11:3351-3364.
44. Barnes PJ, Karin M: Nuclear factor-κB, a pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 1997, 336:1066-1071.
45. Baeuerle PA, Baichwal VR: NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997, 65:111-137.
46. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M: A cytokine responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997, 388:853-862.
47. Mercurio F, Zhu F, Murray BW, Shevchenko A, Bennett BL, Li JW, Young DB, Barbosa M, Mann M, Manning AM, Rao A: IKK-1 and IKK-2: Cytokine-activated IκB kinases essential for NF-κB activation. Science 1997, 278:860-866.
48. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y: Identification of the receptor component of the IκBα-ubiquitin ligase. Nature 1998, 396:590-594. The identification of the E3 ligase that selectively phosphorylates IκB prior to degradation by the 26S proteasome is described.
49. Maniatis T: A ubiquitin ligase complex essential for the NF-κB, wart/wingless, and hedgehog signaling pathways. Genes Dev 1999, 13:505-510. A review of the recent discoveries associated with ubiquitin-dependent proteolysis and the identification of a specific IκB E3 ligase.
50. Malinin NL, Boldin MP, Kovalenko AV, Wallach D: MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997, 385:540-544.
51. Lee FS, Hagler J, Chen ZJ, Maniatis T: Activation of the IkB alpha complex by MEKK1, a kinase of the JNK pathway. Cell 1997, 88:213-222.
52. Baichwal VR, Baeuerle PA: Kinases in pro-inflammatory signal transduction pathways: New opportunities for drug discovery. Annu Rept Med Chem 1998, 33:233-242.
53. Lallena MJ, Diaz-Meco MT, Bren G, Payá CV, Moscat J: Activation of IkappaB kinase beta by protein kinase C isoforms. Mol Cell Biol 1999, 19:2180-2188.
54. Beraud C, Henzel WJ, Baeuerle PA: Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci USA 1999, 96:429-434.
55. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-α. Nature 1998, 396:77-80.
56. Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J, Woolley DE, Davis RW: Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA 1997, 94:2150-2155.